In a filing, X4 Pharmaceuticals Inc revealed its Chief Commercial Officer Baldry Mark acquired Company’s shares for reported $14654.0 on May 17 ’24. In the deal valued at $0.68 per share,21,646 shares were bought. As a result of this transaction, Baldry Mark now holds 115,769 shares worth roughly $ 57884.5.
Then, Baldry Mark bought 13,404 shares, generating $4,598 in total proceeds. Upon buying the shares at $0.34, the Chief Commercial Officer now owns 129,173 shares.
Before that, Ragan Paula sold 76,473 shares. X4 Pharmaceuticals Inc shares valued at $34,719 were divested by the President and CEO at a price of $0.45 per share. As a result of the transaction, Ragan Paula now holds 1,087,386 shares, worth roughly $0.54 million.
B. Riley Securities downgraded its X4 Pharmaceuticals Inc [XFOR] rating to a Neutral from a a Buy in a research note published on December 12, 2023; the price target was decreased to $1 from $3. Cantor Fitzgerald began covering XFOR with “an Overweight” recommendation on December 22, 2022. Piper Sandler started covering the stock on December 12, 2022. It rated XFOR as “an Overweight”.
Price Performance Review of XFOR
On Tuesday, X4 Pharmaceuticals Inc [NASDAQ:XFOR] saw its stock fall -1.97% to $0.50. Over the last five days, the stock has lost -2.14%. X4 Pharmaceuticals Inc shares have fallen nearly -32.05% since the year began. Nevertheless, the stocks have fallen -47.23% over the past one year. While a 52-week high of $1.60 was reached on 01/02/25, a 52-week low of $0.26 was recorded on 01/16/25. SMA at 50 days reached $0.5890, while 200 days put it at $0.6831.
Levels Of Support And Resistance For XFOR Stock
The 24-hour chart illustrates a support level at 0.4780, which if violated will result in even more drops to 0.4575. On the upside, there is a resistance level at 0.5310. A further resistance level may holdings at 0.5635. The Relative Strength Index (RSI) on the 14-day chart is 44.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0652, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.89%. Stochastics %K at 13.97% indicates the stock is a buying.
The most recent change occurred on December 23, 2019 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.
